Your browser doesn't support javascript.
loading
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton, Josephine; Blagih, Julianna; Ennis, Darren; Leung, Elaine; Dowson, Suzanne; Farquharson, Malcolm; Tookman, Laura A; Orange, Clare; Athineos, Dimitris; Mason, Susan; Stevenson, David; Blyth, Karen; Strathdee, Douglas; Balkwill, Frances R; Vousden, Karen; Lockley, Michelle; McNeish, Iain A.
Afiliação
  • Walton J; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Blagih J; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Ennis D; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Leung E; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Dowson S; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Farquharson M; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Tookman LA; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Orange C; Department of Pathology, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Athineos D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Mason S; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Stevenson D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Blyth K; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Strathdee D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Balkwill FR; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Vousden K; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Lockley M; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • McNeish IA; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. iain.mcneish@glasgow.ac.uk.
Cancer Res ; 76(20): 6118-6129, 2016 10 15.
Article em En | MEDLINE | ID: mdl-27530326
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteína Supressora de Tumor p53 / Cistadenocarcinoma Seroso / Proteína BRCA2 / Modelos Animais de Doenças / Sistemas CRISPR-Cas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteína Supressora de Tumor p53 / Cistadenocarcinoma Seroso / Proteína BRCA2 / Modelos Animais de Doenças / Sistemas CRISPR-Cas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cancer Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido